Answers are grounded in this paper and cite their sources.
Investigator-initiated clinical research refers to studies conducted by healthcare institutions that focus on individuals or groups (including medical and health information) as research subjects, covering a wide range of dimensions such as disease diagnosis, treatment, rehabilitation, prognosis, etiology, prevention, and health maintenance. Among these, investigator-initiated trials (IITs), particularly randomized controlled trials (RCTs), serve as a crucial complement to pharmaceutical company-initiated drug clinical trials. Unlike industry-sponsored studies, IITs typically do not focus on profit-making or drug registration. Instead, they primarily involve clinical researches on already marketed drugs, medical devices, or diagnostic reagents, aiming to expand and optimize existing clinical practices with evidence-based medical support [1]. IITs are also a key strategy for driving the high-quality development of public hospitals at various levels. China, as a major country burdened with liver diseases, faces challenges in investigator-initiated clinical trials in the liver disease field, particularly in comparison to the international liver disease community. This editorial discusses the necessity, current status, and challenges of strengthening the development of investigator-initiated RCTs in the liver disease domain in China. It also introduces the Investigator-Initiated Liver Disease Randomized Controlled Trial (LiverRCTIIT) project. In alignment with the “Healthy China 2030” plan, health has become a central factor in promoting holistic human development, serving as a fundamental pillar for economic and social progress. To enhance the quality and efficiency of healthcare, efforts are being made to address clinical needs in major diseases, strengthen the development of clinical specialties, and enhance diagnostic and therapeutic capabilities. Furthermore, the need to advance clinical research and the translational capabilities of high-level hospitals is crucial, which, in turn, fosters the high-quality development of public hospitals. These undertakings reflect a strong commitment to supporting IITs, providing a robust framework for the sustainable growth of clinical research. To enhance clinical diagnosis and treatment, Chinese researchers have initiated numerous internationally leading, high-quality IITs. For instance, in 2023, scholars in the stroke field published eight papers in prestigious journals such as N Engl J Med, Lancet, JAMA, and BMJ, with seven of these being investigator-initiated RCTs [2-9]. One landmark study, published in N Engl J Med in 2022, titled “Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI,” filled a critical gap in international clinical guidelines and marked the first international multicenter trial in the field of cardiac intervention led by a Chinese research team [10]. China is the country with the highest burden of liver disease globally. Chronic liver conditions can progress to cirrhosis and hepatocellular carcinoma, imposing a substantial economic and healthcare burden. In an effort to reduce this burden, Chinese researchers have conducted a considerable number of investigator-initiated clinical studies (including cross-sectional studies, cohort studies, etc.), publishing several high-quality research papers that provide solid evidence for the clinical management of liver disease patients. However, a review of international databases such as PubMed, using keywords like “China,” “Chinese,” “liver disease,” “hepatocellular carcinoma,” and “randomized controlled trial” over the past decade (2015–2024), reveals a notable dearth of investigator-initiated RCTs in liver disease led by Chinese researchers, particularly in high-impact journals such as N Engl J Med, Lancet, JAMA, and BMJ. Despite the urgent need for high-quality RCTs in liver disease, the number of such trials remains limited in China. The main challenges contributing to this situation include: (1) Limited funding for researchers: The establishment of electronic data collection systems and the costs of major diagnostic tests and treatments often require researchers to secure substantial funding independently; (2) Difficulty in multi-center collaboration: Due to the relatively small patient cohorts at individual centers, it is difficult to meet the sample size requirements needed for RCTs; (3) Quality control challenges: Ensuring data quality and protocol adherence depends heavily on the internal systems of the research team or institution, with a lack of regulatory oversight akin to that provided by drug regulatory agencies; (4) Suboptimal team structure: Many researchers are clinicians without the support of methodological experts, limiting the scientific rigor of trial design and execution; and (5) Lack of experience and training: There is a scarcity of institutions or training programs that provide systematic methodological training for conducting RCTs, which hinders the development of investigator-initiated trials. In light of these challenges, the Liver Health Consortium in China (CHESS) and the National Center for Infectious Disease Medicine (Beijing) have jointly initiated the “Investigator-Initiated Liver Disease Randomized Controlled Trial (LiverRCTIIT)” program. The objective of this initiative is to focus on key clinical issues in the prevention and treatment of liver disease in China and to support the initiation of high-quality investigator-led RCTs. This project aims to provide funding and academic platforms for researchers dedicated to improving liver disease management practices both in China and globally. Additionally, the LiverRCTIIT project will establish a collaborative network for liver disease RCTs, offering methodological education, technical guidance, and quality control assistance. This collaboration aims to overcome the existing barriers and advance the development of RCTs in the liver disease field within China. Conceptualization and writing the original draft: Xiaolong Qi. Review and editing: Ronghua Jin. All the authors have approved this version of the manuscript. Thanks to Dr. Bingtian Dong from the First Affiliated Hospital of Anhui Medical University for his academic support of this article. The authors have nothing to report. Xiaolong Qi is the Editor-in-Chief of Portal Hypertension & Cirrhosis. He is therefore excluded from the peer-review process and all editorial decisions related to the publication of this manuscript. The other author declares no conflicts of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: